CN Patent

CN103476759B — 取代的4-芳基-n-苯基-1,3,5-三嗪-2-胺

Assigned to Bayer Pharma AG · Expires 2016-03-16 · 10y expired

What this patent protects

本发明涉及如本发明所述和所定义的通式(I)的取代的4-芳基-N-苯基-1,3,5-三嗪-2-胺，及其制备方法，其用于病症特别是过度增殖性病症和/或病毒诱导的感染性疾病和/或心血管疾病的治疗和/或预防的应用。本发明还涉及可用于制备所述通式(I)的化合物的制备的中间体化合物。

USPTO Abstract

本发明涉及如本发明所述和所定义的通式(I)的取代的4-芳基-N-苯基-1,3,5-三嗪-2-胺，及其制备方法，其用于病症特别是过度增殖性病症和/或病毒诱导的感染性疾病和/或心血管疾病的治疗和/或预防的应用。本发明还涉及可用于制备所述通式(I)的化合物的制备的中间体化合物。

Drugs covered by this patent

momelotinib-dihydrochloride (MOMELOTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN103476759B
Jurisdiction: CN
Classification: —
Expires: 2016-03-16
Drug substance claim: No
Drug product claim: No
Assignee: Bayer Pharma AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.